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Classic tumor therapy, consisting of cytotoxic agents and/or targeted therapy, has not
overcome therapeutic limitations like poor risk genetic parameters, genetic heterogeneity
at different metastatic sites or the problem of undruggable targets. Here we summarize
data and trials principally following a completely different treatment concept tackling
systems biologic processes: the principle of communicative reprogramming of tumor
tissues, i.e., anakoinosis (ancient greek for communication), aims at establishing novel
communicative behavior of tumor tissue, the hosting organ and organism via re-modeling
gene expression, thus recovering differentiation, and apoptosis competence leading to
cancer control – in contrast to an immediate, “poisoning” with maximal tolerable doses of
targeted or cytotoxic therapies. Therefore, we introduce the term “Master modulators” for
drugs or drug combinations promoting evolutionary processes or regulating homeostatic
pathways. These “master modulators” comprise a broad diversity of drugs, characterized
by the capacity for reprogramming tumor tissues, i.e., transcriptional modulators,
metronomic low-dose chemotherapy, epigenetically modifying agents, protein binding
pro-anakoinotic drugs, such as COX-2 inhibitors, IMiDs etc., or for example differentiation
inducing therapies. Data on 97 anakoinosis inducing schedules indicate a favorable
toxicity profile: The combined administration of master modulators, frequently (with
poor or no monoactivity) may even induce continuous complete remission in refractory
metastatic neoplasia, irrespectively of the tumor type. That means recessive components
of the tumor, successively developing during tumor ontogenesis, are accessible by
regulatory active drug combinations in a therapeutically meaningful way. Drug selection is
now dependent on situative systems characteristics, to less extent histology dependent.
To sum up, anakoinosis represents a new substantive therapy principle besides novel
targeted therapies.
Keywords: Anakoinosis, communicative reprogramming, transcriptional modulators, metronomic low-dose
chemotherapy, glitazones, all-trans retinoic acid, COX-2 inhibitor, master modulators
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INTRODUCTION
Each cancer treatment strategy is based on simplifying
methodological assumptions (Reichle, 2010). One basic
consideration relies on the suggestion that essential tumor-
promoting pathways are ubiquitously distributed at metastatic
tumor sites and should be shut off, or single cell types within
a tumor disease should be knocked out via specific targets.
Molecular tumor boards and corresponding “intelligent”
treatment algorithms are the logic consequence of this
assumption.
Therapeutic limitations of classic targeted tumor therapies
are (molecular-) genetic heterogeneity at metastatic sites, poor
risk genetic parameters as well as context-dependent validity
and denotation of tumor-promoting aberrations and targets
(dependent of the genetic background) (Box 1). This fact may be
exemplified by context-dependent efficacy of B-RAF inhibitors in
different tumor histologies (Flaherty et al., 2010; Kopetz et al.,
2015).
Here we summarize trials principally following a completely
different treatment concept. All the mentioned schedules
are tackling systems biologic processes, such as dysregulated
homeostatic pathways in tumors or are recalling or perfectioning
patterns of evolutionary processes (“metabolism of evolution”)
provided by single cell types and cell systems in a tumor
(Box 1). Thus, also drugs, particularly drug combinations, may
be introduced with biomodulatory activity, so called master
modulators of tissues, promoting evolutionary processes or
regulating homeostatic pathways for treating metastatic and
refractory metastatic disease or hematologic neoplasia (Hart
et al., 2015).
Master modulators of tumor tissues, such as transcriptional
modulators, hormones, cytokines, vitamins, epigenetically active
drugs, metronomic low-dose chemotherapy and protein-binding
drugs cyclooxygenase-2 (COX-2) inhibitors, IMiDs, arsenic
trioxide etc. are aiming at reconditioning tumor tissue into a
controlled phenotype, thereby diversifying palliative care, or even
inducing continuous complete remission (Table 1; Box 1; Hart
et al., 2015). Master modulators may therapeutically cope with
different, but iterative patterns and physical constitutions of
hallmarks of cancer supported by quite heterogeneous tumor
genotypes. Those different patterns of acquired chromosomal
aberrations may support a unique hallmark, exemplified in acute
leukemias by the rapidly displacing growth in the bone marrow.
Basis for the concerted regulatory activity profile of
master modulators are during tumor ontogenesis developing
dysregulated transcription programs, networks of pathways and
interlaced communication routes among cancer cells, adjacent
stroma cells, tumor bearing organ and organism.
Communicative reprogramming of tumor tissues, i.e.,
anakoinosis, aims at establishing novel communicative behavior
of tumor tissue, the hosting organ and organism via re-modeling
gene expression, thus recovering differentiation, and apoptosis
competence leading to cancer control (Box 1; Hart et al., 2015).
The presented tool of clinical observations on anakoinosis
inducing therapy approaches reveals that tumor tissue provides
an extensive design space, including the interaction of tumor
and tumor bearing organ and organism (Hart et al., 2015).
The biological necessity of tumor site to respond with clinically
relevant changes in tumor behavior following exposure to
master modulators that means anakoinosis-inducing drugs,
is predefined by not necessarily histologically determined
prerequisites guiding communication.
MASTER MODULATORS, THE BACKBONE
OF ANAKOINOSIS INDUCING THERAPIES
Broad Repertoire of Possible Approaches
for Inducing Anakoinosis: Diversity of
Master Modulators of Tumor Tissues
The instruments for inducing anakoinosis are multifaceted
and still insufficiently explored. An important distinguishing
characteristic, in contrast to classic targeted therapy, is
the generally observed minor monoactivity, but frequently
“concerted” activity profile of single pro-anakoinotic drugs
(Tables I–VIII), the possibility for successfully administering
agonistic, immunomodulatory and anti-inflammatory drugs and
the modest toxicity profile.
Starting point for the current review are a series of
systematically developed clinical trials on refractory metastatic
tumor diseases including at least one nuclear receptor agonist
and metronomic low-dose chemotherapy or epigenetically active
drugs as pro-anakoinotic therapy approaches (Hart et al., 2015,
2016; Walter et al., 2017).
Pro-anakoinotic schedules include epigenetically and
transcriptionally active drugs, such as agonists of nuclear
transcription factors (glitazones, all-trans retinoic acid,
bexarotene, glucocorticoids, vitamin D etc.), but also
cytokines (e.g., interferon-α, Interleukin-2 etc.) and vitamins.
Transcriptional modulators have in common that they may
up-regulate tumor suppressor genes (Berger et al., 2011). Thus,
also differentiation inducing liposomal encapsulated small
oligonucleotide encoding small activating RNAs (MTL-CEBPA)
are pro-anakoinotic drugs (Reebye et al., 2018; Sarker et al.,
2018). Table V exemplarily summarizes first clinical results on
MTL-CEBPA or ivosidenib, an IDH (Isocitrat-Dehydrogenase)
inhibitor as differentiation inducing drugs.
In addition, metabolic modulators have been introduced, like
metformin (Attia et al., 2008; Chae et al., 2016; Lecarpentier
et al., 2017), which may also act transcriptionally (Coyle et al.,
2016) and statins. IMiDs, COX-2 inhibitors and arsenic trioxide
represent protein-binding pro-anakoinotic drugs.
Anakoinosis drugs include epigenetically acting agents, e.g.,
azacitidine, decitabine, valproic acid etc. acing broadly on
chromatin, but also, (here, only mentioned) small molecules
targeting specific epigenetic mechanisms, e.g., by inhibiting BET
bromodomain transcriptional regulators; EZH2 (Enhancer of
zeste homolog 2); DOT1L (DOT1-like, histone H3 methyl-
transferase); IDH (Dawson et al., 2011; McCabe et al., 2012; Kim
et al., 2015; Dang et al., 2016; Tögel et al., 2016; DiNardo et al.,
2018).
The pro-anakoinotic activity of metronomic low-
dose chemotherapies with their pleiotropic angiostatic,
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Box 1 | Explanation of communication terms.
Communication-associated terms Explanation
Anakoinosis Communicatively reprogramming biologic systems, here tumor systems. Anakoinosis aims at establishing novel
communicative behavior of tumor tissue
Validity and denotation Validity of systems objects, functions and hubs: Availability on demand at distinct systems stages; denotation:
Current functional impact at a distinct systems stage, e.g., of potentially tumor-promoting pathways. In the
bio-world, presence and functioning of an object (e.g., an enzyme), respectively
Rationalizations Describe the physical organization of tumor-associated normative notions (e.g., hallmarks of cancer); are to some
degree histology- and genotype-independent; may be re-directed and reorganized by anakoinosis
Metabolism of evolution The sum of extrinsically, i.e., therapeutically, and intrinsically inducible evolutionary processes within the
tumor environment (tumor stroma, hosting organ, distant organ sites)
Modularity Modularity describes the degree and specificity to which systems’ objects, i.e., cells, pathways, molecules,
therapeutic targets etc. may be communicatively rededicated by anakoinosis
Pro-anakoinotic therapeutic tools (examples) Transcriptional modulators
Nuclear receptor agonists, antagonists
Metronomic low-dose chemotherapy
Cyclooxygenase-2 inhibitors
IMiDs
Arsenic trioxide
Liposomal encapsulated small oligonucleotide encoding small activating RNAs
immunomodulatory, anti-inflammatory and drug specific
effects, may be particularly exploited in combination with
further master modulators (Hart et al., 2015). Clarithromycin,
metronomically administered, shows similar activity profiles
(Hart et al., 2015; van Nuffel et al., 2015; Romiti et al., 2017).
Some pro-anakoinotic therapeutics on protein-binding level are
arsenic trioxide, IMiDs, and COX-2 inhibitors are approved.
Still in pre-clinical evaluation is a novel technology aiming
at the targeted shut off transcriptional modulators with small
molecules (Bradner et al., 2017; Tables 1, 2).
Frequently “old drugs” are used within pro-anakoinotic
schedules in quite new functions, what is called “drug
repurposing” (Bertolini et al., 2015). For the main part,
the present review compiles drugs with poor monoactivity,
particularly, also with respect to the scheduled dose reductions
of single drugs for long-term administration (Hart et al., 2015).
The metronomic scheduling of drugs is an important
component of pro-anakoinotic therapy approaches (André et al.,
2017). Although in some tumor diseases rapid responses may
be achieved within a 3–4-week cycle, other responses occur
delayed, showing that a continuous systems therapeutic approach
is necessary (Hart et al., 2015).
Clinical results of the reviewed therapeutic concepts
integrating anakoinosis-inducing drug combinations indicate
that features of palliative tumor care may diversified in a
therapeutically meaningful way and that pro-anakoinotic
schedules even have the capacity for inducing (continuous)
complete remission (Hart et al., 2015; Thomas et al., 2015; Mayer
et al., 2017).
Reviewed Pro-anakoinotic Schedules for
Explicating the Novel Treatment Approach
For explicating the novel methodological approach, we
summarized data on the clinical administration of master
modulators, i.e., transcriptional modulators in monotherapy
or in various combinations (Table 1), (1) combined with
metronomic low-dose chemotherapy, (2) pulsed chemotherapy,
(3) demethylating agents, (4) classic targeted therapies or
(5) protein-binding pro-anakoinotic drugs (arsenic trioxide,
IMiDs, COX-2 inhibitors) (Tables I–VIII). Agonists and
antagonists of transcriptional modulators, metronomic low-dose
chemotherapy, epigenetically active agents, protein- binding
pro-anakoinotic drugs, but also classic targeted therapies
inducing for example differentiation (Table V) are considered as
master modulators exploiting the tumors design space.
Available study data are unsuitable for presentation in a
Cochrane or PRISMA analysis due to the diversity of schedules
and the respective low patient numbers treated in each trial.
Likewise, it would go beyond the scope of this study to give a
comprehensive review on single master modulators.
Just the diversity of response patterns following anakoinosis-
inducing schedules, their successful administration independent
of tumor histology, the possibility for classifying responses
according to operated communication tools, or for elaborating
mechanisms of action, may highlight the sum of reported pro-
anakoinotic treatment approaches as unique therapeutic pillar
(Tables 1, 2).
Concerning transcriptional modulators, the explication of
the novel methodological approach is restricted to selected
transcriptional modulators in mono- or combination therapy,
i.e., glitazones, glucocorticoids, vitamin D, somatostatin
analogs, melatonin, interferon-alpha, estrogen, luteinizing
hormone-releasing hormone (LHRH) agonist, retinoic acid and
bexarotene.
For clarity, we do not consider (nuclear) receptor antagonists
as clinical data on these drugs well established their clinical
benefit, for example in breast and prostate cancer. In addition,
not included are studies using COX-2 inhibitors plus pulsed
chemotherapy, metformin or statins, also for reasons of
comprehensibility.
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TABLE 1 | Master modulators including transcriptional modulators in 97 clinical trials: Master modulators are transcriptional modulators (hormones, cytokines, vitamins
etc.), metronomic low-dose chemotherapy, protein-binding drugs (arsenic trioxide, COX-2 inhibitors, IMiDs etc.), metabolic active drugs, such as PPAR gamma/α
agonists, statins, and metformin (interventional statin and metformin trials are not included in the review; also, not included nuclear receptor antagonists).
Ninety-seven studies including master modulators (25 histologic entities). Dysregulated transcription programs: Cancer cells are highly dependent on
regulators of gene expression.
Schedule of master
modulators
No of
studies
Drugs (approved in bold) Comments
Transcriptional modulator as
monotherapy (Light blue
Table I-VIII)
26 • Vitamin D
• Interferon-alpha
• LHRH agonist
• Somatostatin
• All-trans retinoic acid
•Estrogen
• Six trials on
pioglitazone,
rosiglitazone,
troglitazone
• Bexaroten
•(MTL-CEBPA; IDH
inhibitor)
No monoactivity:
•Glitazones in four
• histologic tumor types
• Estrogen
Simultaneous administration
of two or more transcriptional
modulators plus/minus
additional master modulators
(without metronomic
chmotherapy) (Green Table II-V)
17
Agonistic acting drugs
•Dexamethasone/combined with IMiD
•LHRH agonist/combined with Vitamin D or
dexamethasone/somatostatin or Interleukin-2 (IL-2)
•IFN-alpha/ combined with somatostatin or
dexamethasone or IL-2
• Somatostatin/ combined with estrogen or IFN-alpha
•All-trans retinoic acid/ combined with arsenic
trioxide or interferon-alpha
Combinations may be equally
efficacious compared to
standard chemotherapy (Renal
clear cell carcinoma,
castration-resistant prostate
cancer, neuroendocrine
tumors, acute promyelocytic
leukemia: phase III trial)
One transcriptional
modulator plus/minus IMiD,
COX-2 inhibitor plus
metronomic low-dose
chemotherapy (Violet
Table I-VIII)
13 •Troglitazone or pioglitazone
• Interferon-alpha
• Thalidomide/combined with celecoxib
•Pioglitazone/combined with COX-2 inhibitor
Thiazolidinediones highly
efficacious in respective
combinations
Multiple transcriptional
modulators plus/minus other
master modulators plus
metronomic low-dose
chemotherapy (Red Table I-III)
5 •Pioglitazone/ combined with interferon-alpha or
dexamethasone
•Vitamin D/fenofibrate/retinoic acid (COMBAT trial)
Continuous complete remission,
active chronification in refractory
disease possible
Master modulators plus
targeted therapy (Brown
Table I-VIII)
18 Propranolol; temsirolimus; everolimus; imatinib;
bortezomib; bcl2-
antisense; blinatumumab; sunitinib; bevacizumab;
tamoxifen; letrozol; denileukin difitox; veliparib
Randomized phase III trial,
imatinb/pioglitazone
Master modulator(s) plus
pulsed chemotherapy (Dark blue
Table II-VIII)
14 •Prednisolone
•Methylprednisolone/IL-2
•Somatostatin
•Retinoic acid
•Melatonin
•Vitamin D
•LHRH agonist
Less efficacious combinations
•Somatostatin/retinoic
acid/melatonin/VitD/bromocriptin;
•Retinoic acid/interferon-alpha
•Metronomic low-dose
chemotherapy
Transcriptional modulator(s)
plus demethylating or
deacetylating agent (Yellow
Table VI)
4 • Azacitidine/all-trans retinoic
acid/pioglitazone
• Valprionic acid/ retinoic acid or bexaroten
• Vorinostat/bexaroten/fenofibrate
Induction of complete remission
possible in refractory disease
For a better assessment of the clinical results on combinations
of master modulators, particularly transcriptional modulators,
additional data from randomized clinical trials are given
comparing metronomic chemotherapy ± targeted therapies or
metronomic with pulsed chemotherapy in Table VIII.
Monoactivity of Anakoinosis Inducing
Drugs
Twenty-four reviewed studies included one transcriptional
modulator, as monotherapy for cancer treatment, either a
glitazone, a hormone or cytokine. Table 1 indicates the
administered master modulators.
Monoactivity of glitazones or estrogen in cancer patients
is very modest, whereas strong activity is well established in
single tumor histologies for dexamethasone, LHRH agonist,
somatostatin, and bexarotene (Tables IA/B, II, IV–VII; Querfeld
et al., 2006; Sharma et al., 2008; Sidéris et al., 2012). The
administration of interferon-α is superseded for melanoma or
multiple myeloma (Browman et al., 1995; Di Trolio et al.,
2015).
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TABLE 2 | The tool of anakoinosis inducing therapies may be separated as novel treatment pillar.
Treatment paradigms/Diagnostics/Therapeutics
Three treatment pillars for systemic tumor therapy
Treatment characteristics Classic targeted
therapy:
• Shutting off
• Pathways
• Cells
• Reactivating
immune system
• Classic targeted
immunotherapy
Anakoinosis:
• Communicative
reprogramming of tumor
tissue and host
Paradigms Pathology Pathology: Pathophysiology:
• Histology
• Genome-centric:
Uni-directional
targeting
• Immune escape
(multifactorial process)
• Multi-dimensional
communication
• Induction and perfection
of evolutionary processes
Diagnostics Situative snapshots Immunologically
accessible targets
Transcriptional
dys-regulation
• (Immuno-) histology
• (Molecular-) genetics
• Homeostatic pathways
• Tumor suppressor genes
Therapeutics Targeted therapies: Cellular therapies,
antibodies etc.:
Master modulators
• Blockade of
pathways
• Shutting off cells
• Modulation of
immune response
• Shutting off cells
• Of tissue homeostasis
(poor monoactivity, but
concerted activity)
Oncological praxis does still not integrate metronomic
low-dose chemotherapy, as routine therapeutic concept: Even
combination therapies with classic targeted approaches or
pulsed chemotherapy often show poor results in randomized
comparison (Table VIII). Even more so, there is a growing
number of combinatory schedules (Kerbel and Shaked, 2017),
which shall bring to the fore the metronomic idea, meanwhile
advanced in years, on the background of novel pharmacokinetic
data (Bocci and Kerbel, 2016; Ciccolini et al., 2017).
Like metronomic chemotherapy, clarithromycin has a multi-
functional activity profile and is currently being used in
anakoinosis inducing schedules (ClinicalTrials.gov Identifier:
NCT02852083) (Table 1; van Nuffel et al., 2015).
Demethylating and deacetylating agents show monoactivity
in the range of commonly approved dose levels (Nervi et al.,
2015). However, in anakoinosis inducing schedules much lower
doses are going to be established (ClinicalTrials.gov Identifier:
NCT02942758) (Thomas et al., 2015).
Agonists of “adopted” orphan receptors commonly have poor
monoactivity in interventional cancer trials (Smith et al., 2004;
Di Masi et al., 2015), in contrast to hormones and cytokines
(McDermott et al., 2005; Mitchell et al., 2005). Particularly,
dexamethasone plays a decisive role in the induction treatment
for acute lymphocytic leukemia or multiple myeloma (Mitchell
et al., 2005).
Metabolically active drugs, such as metformin or PPARγ/α
agonists, are considered as chemopreventive agents (Fröhlich and
Wahl, 2015; Higurashi et al., 2016). Metformin may prolong
survival in cancer patients following surgery, but only in distinct
histologic tumor types, as retrospective studies are indicating
(Coyle et al., 2016).
Among the protein-binding drugs, arsenic trioxide and
immunomodulatory imide drugs (IMiDs) have known
monoactivity in hematologic diseases (Quach et al., 2010;
Iland and Seymour, 2013) but both drugs are commonly
administered combined with transcriptional modulators, all-
trans-retinoic acid and dexamethasone, respectively (Lo-Coco
et al., 2013; Benboubker et al., 2014).
Simultaneous Administration of Two or
More Transcriptional Modulators
Plus/Minus Additional Master Modulators
(Without Metronomic Low-Dose
Chemotherapy)
Synergistic activity of dual transcriptional modulation has
been well established in pre-clinical studies, for example for
pioglitazone and all-trans retinoic acid in tumor cell lines
of different histology (Papi et al., 2009, 2010, 2012, 2013),
but also for glitazones in combination with chemotherapy
(Elrod and Sun, 2008). Clinical trial designs translated these
pre-clinical results hesitantly. Predominantly drugs, coming
from immunomodulatory approaches (Il-2, interferon-α) found
their way into combinatorial use (McDermott et al., 2005).
Somatostatin analogs are administered besides their original
application field, e.g., neuroendocrine tumors, also in castration-
resistant prostate cancer, here in combination with estrogen
or dexamethasone and LHRH analogs (Sciarra et al., 2004;
Koutsilieris et al., 2006). In castration-resistant prostate cancer,
the combination of transcriptional modulators alone may
induce durable response (Table V; Koutsilieris et al., 2006).
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TABLE IA | Communicative reprogramming of tumor disease.
Glitazones IA
Neoplasia No pts Chemotherapy
(metronomic)*
Transcriptional
modulators
Small molecule Best response Publication
SARCOMAS
Liposarcomas,
intermediate to
high-grade (case
reports)
– – • Troglitazone – Histological and
biochemical differentiation
Tontonoz et al.,
1997
Liposarcoma 3 Trofosfamide* • Troglitazone – Lineage-appropriate
differentiation can be
induced pharmacologically
in a human solid tumor.
Demetri et al.,
1999
Liposarcoma (Phase II
study)
12 – • Rosiglitazone – Rosiglitazone is not effective
as an antitumoral drug in the
treatment of liposarcomas
Debrock et al.,
2003
Kaposi sarcoma,
refractory
1 Trofosfamide* • Pioglitazone • COX-2 inhibitor Partial remission Coras et al.,
2004
(Hem-)angiosarcomas 12) Trofosfamide* • Pioglitazone • COX-2 inhibitor Continuos complete
remission Vogt et al., 2003
Angiosarcoma 7 Vinblastine*
Methotrexate*
– • Propranolol Complete remission Pasquier et al.,
2016
BREAST CANCER
Refractory breast
cancer (Phase II study)
22 – • Troglitazone – No significant effect Burstein et al.,
2003
MELANOMA
Melanoma III (versus
DTIC), phase II
ClinicalTrials.gov:NCT01614301
6 Trofosfamide* • Pioglitazone Temsirolimus
COX-2 inhibitor
Partial remission,
Resolution of cachexia
Hart et al., 2016
MELANOMA (RANDOMIZED)
Melanoma II Arm M
Arm A/M
35
32
Trofosfamide*
Trofosfamide*
–
Pioglitazone
-
• COX-2 inhibitor
Stable disease Partial
remission
Reichle et al.,
2007b
HEPATOCELLULAR CARCINOMA
Hepatocellular
carcinoma
38 • Capecitabine* • Pioglitazone • COX-2 inhibitor Partial remission Walter et al.,
2017
CHOLANGIOCELLULAR CARCINOMA
Cholangiocellular
carcinoma
21 Trofosfamide* • Pioglitazone • COX-2 inhibitor Partial remission Reichle et al.,
2010
COLORECTAL CANCER
Chemotherapy-
resistant metastatic
colorectal cancer
(phase II study)
25 – • Troglitazone – Not active for the treatment
of metastatic colorectal
cancer
Kulke et al.,
2002
RENAL CLEAR CELL CARCINOMA (HISTORIC COMPARISON)
Renal clear cell
carcinoma, relapsed
18 Capecitabine* • Pioglitazone • COX-2 inhibitor Partial remission Reichle et al.,
2007a
Renal clear cell
carinoma, relapsed
33 Capecitabine* Pioglitazone
Interferonalpha
• COX-2 inhibitor Continuous complete
remission
Walter et al.,
2012; Hart et al.,
2016
Anakoinotic therapy approaches sorted by transcriptional modulator and tumor disease. For comparison of clinical results on pro-anakoinotic therapies, the tables additionally
indicate data on metronomic chemotherapy alone. Light blue: Monotherapy with transcriptional modulators; green: Several transcriptional modulators or master modulators
(without metronomic chemotherapy); violet: Metronomic chemotherapy plus transcriptional modulator/ or other master modulators; red: Metronomic chemotherapy and multiple
transcriptional modulators or master modulators; brown:Master modulators plus targeted therapy; dark blue: Pulsed chemotherapy plus master modulator(s); yellow: Demethylating
agent/deacetylating agent plus transcriptional modulators.
Combinations of estrogen with gestagen failed to show activity
in endometrial carcinoma (Chlebowski et al., 2016).
Interestingly, interferon-α is active in renal cell carcinoma,
both in combination with retinoids or pioglitazone (Buer et al.,
1995; Walter et al., 2012; Aviles et al., 2015). Topical application
of interferon-α and retinoids is helpful in corneal epithelial
neoplasia (Krilis et al., 2012).
Standard schedules for the treatment of multiple myeloma
include dexamethasone and IMiDs, also for maintenance therapy
(Roussel et al., 2014).
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TABLE IB | Communicative reprogramming of tumor disease.
Glitazones IB
Neoplasia No pts Chemotherapy
(metronomic)*
Transcriptional
modulators
Small molecule Best response Publication
PROSTATE CANCER
Prostate cancer 41 – • Troglitazone – Lengthened
stabilization of
prostate-specific
antigen
Mueller et al.,
2000
Castration-resistant
prostate cancer
61 • Treosulfan* • Pioglitazone,
•Dexamethasone
• COX-2 inhibitor
• Imatinib
Long-term
tumor control at
minimal disease
Vogelhuber
et al., 2015
Castration-resistant
prostate cancer
36 • Capecitabine* • Pioglitazone,
•Dexamethasone
• COX-2
inhibitor
Long-term
tumor control
Vogt T. et al.,
2006; Walter B.
et al., 2010
PROSTATE CARCINOMA (RANDOMIZED)
Rising serum
prostate-specific
antigen level after
radical prostatectomy
and/or radiation
therapy
106 - • Rosiglitazone
versus
• Placebo
- Rosiglitazone did
not increase PSA
doubling time or
prolong the time to
disease
progression
Smith et al.,
2004
GASTRIC CANCER (RANDOMIZED)
Gastric cancer Arm
A/M
Arm M
21
21
• Capecitabine*
• Capecitabine*
• Pioglitazone - • COX-2
inhibitor -
Partial
remission,
pioglitazone no
impact
Reichle et al.,
2009
MULTIPLE MYELOMA
Multiple myeloma,
third-line
Clinicaltrials.gov,
NCT001010243
6 • Treosulfan* • Pioglitazone,
•Dexamethasone
• Lenalidomide Complete
remission
Reichle et al.,
2012
LANGERHANS CELL HISTIOCYTOSIS
Langerhans cell
histiocytosis, refractory
2+7 • Trofosfamide* • Pioglitazone
•Dexamethasone
• COX-2
inhibitor
Continuous
complete
remission
Reichle et al.,
2005; Hart
et al., 2015;
Heudobler
et al., 2016
HODGKIN LYMPHOMA
Hodgkin lymphoma,
refractory
3 • Treosulfan* • Pioglitazone,
• Dexamethasone
• COX-2
inhibitor
• Everolimus
Continuous
complete
remission
Ugocsai et al.,
2016
CHRONIC MYELOCYTIC LEUKEMIA
Chronic myelocytic
leukemia without
moleclar CR
24 – • Pioglitazone • Imatinib Molecular
complete
remission (54%)
Prost et al.,
2015
GLIOBLASTOMA
Glioblastoma,
refractory
14 • Capecitabine* • Pioglitazone • COX-2
inhibitor
Disease
stabilization
Hau et al., 2007
GLIOBLASTOMA (RANDOMIZED)
Glioblastoma 85 Temozolomide*(Tem)
versus
Dose dense Tem
• Sequentially
13-cis-retinoic
acid*
- No benefit of
metronomic
chemotherapy in
maintenance
Clarke et al.,
2009
Transcriptional Modulators Combined With
Metronomic Low-Dose Chemotherapy
Adding transcriptional modulators to metronomic low-dose
chemotherapy schedules even led to complete remissions
in a series of phase II trials for histologically quite different
refractory tumor entities (Hart et al., 2015). Schedules
included metronomic low-dose chemotherapy, COX-2
inhibitor and transcriptional modulators. In single patients
with Langerhans cell histiocytosis, renal clear cell carcinoma,
in epithelioid, less differentiated angiosarcoma, these schedules
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TABLE II | Communicative reprogramming of tumor disease.
Glucocorticoids
Neoplasia No pts Chemotherapy Transcriptional
modulators
Small molecule Best response Publication
MULTIPLE MYELOMA (RANDOMIZED)
Multiple myeloma – – • Dexamethasone
• versus
Combination
• + different
targeted therapies
Most combinations are
superior to
dexamethasone alone
van Beurden-Tan
et al., 2017
Relapsed multiple
myeloma
353 – • Dexamethasone
• versus
Dexamethasone only
• Lenalidomide Lenalidomide plus
dexamethasone is
superior
Weber et al., 2007
Relapsed or refractory
multiple myeloma
351 – • Dexamethasone
Versus
• Dexamethasone
only
• Lenalidomide Lenalidomide plus
dexamethasone is
more effective than
high-dose
dexamethasone alone
Dimopoulos et al.,
2007
Relapsed and
refractory multiple
myeloma
302 – • Dexamethasone
• versus
high-dose
dexamethasone
• Pomalidomide
• No pomalidomide
Pomalidomide plus
low-dose
dexamethasone, new
treatment option
San Miguel et al.,
2013
Relapsed multiple
myeloma
669 – • Bortezomib
or high-dose
dexamethasone
• Bortezomib Bortezomib is superior
to high-dose
dexamethasone
Richardson et al.,
2005
Advanced multiple
myeloma
224 – • Dexamethasone ±
Oblimersen sodium
• Oblimersen sodium
(bcl-2 antisense
oligonucleotide
No significant
differences between
the two groups in TTP
or objective response
rate
Chanan-Khan et al.,
2009
LYMPHOMA (RANDOMIZED)
Elderly patients with
aggressive
non-Hodgkin’s
lymphoma
453 Chemotherapy A
Chemotherapy B
• Prednisolone
• Prednisolone
– Slightly longer survival
was observed for
patients treated with an
anthracycline-
containing
regimen
Bastion et al., 1997
LYMPHOMA
Refractory chronic
lymphocytic leukemia
14 - • High dose methyl-
prednisolone
– HDMP may be
beneficial in the
treatment of refractory
CLL but is of no value
in CLL/PL.
Thornton et al., 1999.
Diffuse large B-cell
lymphoma
21 – • Dexamethasone
(supportive)
• Blinatumomab Complete remission
due to blinatumumab
Viardot et al., 2016
Hodgkin disease Review Chemotherapy • Prednisolone ± Continuous complete
remission, decisive is
kind of chemotherapy
Ansell, 2015
ACUTE LYMPHOBLASTIC LEUKEMIA (RANDOMIZED)
Childhood acute
lymphoblastic leukemia
1603 – • Dexamethasone
versus
• Prednisolone
– Dexamethasone led
to a significant
decrease in the risk
of relapse for all
risk-groups
Mitchell et al., 2005
induced continuous complete remission (Vogt et al., 2003;
Coras et al., 2004; Reichle et al., 2005; Heudobler et al.,
2016).
It was only after the addition of interferon-α to metronomic
chemotherapy plus pioglitazone and COX-2 inhibitor that
continuous complete remissions occurred in metastatic
renal clear cell carcinoma (Walter et al., 2012; Hart et al.,
2015). This example clinically shows the pro-anakoinotic
synergy effects of transcriptional modulators. Induction of
continuous complete remission with dual transcriptional
modulation only, supports current experimental data,
showing that PPARγ plays neither a tumor-suppressive nor
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TABLE III | Communicative reprogramming of tumor disease.
Vitamin D
Neoplasia No pts Chemotherapy
(metronomic*)
Transcriptional
modulators
Small molecule Best response Publication
CANCER
Reducing cancer risk,
progression
– – • Vitamin D – Possible therapeutic
benefit
Feldman et al., 2014
Relapsing/refractory
malignancies
(COMBAT:“Combined
oral metronomic
biodifferentiating
anti-angiogenic
treatment“)
74 Temozolomide*
Etoposide*
• Vitamin D
• Fenofibrate
• Retinoic acid
• Celecoxib Complete remission Zapletalova et al.,
2012
Cancer Review – • LHRH agonist,
• Vitamin D
– Osteoporosis
prophylaxis
Nicolini et al., 2016
SARCOMA
Kaposi sarcoma 8 – • Vitamin D(3)
receptor agonist
– The antitumor activity:
topical application
Masood et al., 2000
SOMATOSTATIN analog, melatonin
Neoplasia No Chemo-therapy Transcriptional
modulators
Small molecule Best response Publication
NEUROENDOCRINE TUMORS
Neuroendocrine tumors Meta-analysis – Somatostatin analog - Stable disease: 67% of
patients
Sidéris et al., 2012
Neuroendocrine tumors Meta-analysis Somatostatin analog mTOR inhibitor Approved Bousquet et al., 2012
Metastatic endocrine
tumors
Review – Low-dose
subcutaneous
interleukin-2,
melatonin
– Partial response Lissoni et al., 1995
Gastroenteropancreatic
neuroendocrine
carcinoma
(randomized)
Review – • Interferon-alpha
• Somatostatin
analog
– No statistically
significant survival
benefit compared to
single agent
Fazio et al., 2007
Neuroendocrine tumors
(randomized)
80 – • Lanreotide versus
• Interferon-alpha
versus
• Lanreotide,
IFN-alpha
– No difference in
response
Faiss et al., 2003
CASTRATION-RESISTANT PROSTATE CANCER (RANDOMIZED)
Castration-resistant
prostate cancer
(randomized)
40 Estramustine,
etoposide versus
• LHRH analog
• Somatostatin
analog
• Dexamethasone
– Equally effective
compared to salvage
chemotherapy
Dimopoulos et al.,
2004
an oncogenic role in advanced renal clear cell carcinoma,
and that single-agent PPARγ agonists are unlikely to be
effective for the treatment of this disease (Sanchez et al.,
2018).
In a series of advanced and refractory hematologic diseases
and solid tumors, combination therapies of pioglitazone with
dexamethasone or interferon-α or all-trans-retinoic acid could
be successfully used in addition to metronomic low-dose
chemotherapy or azacitidine. Figure 1 indicates diversified
outcomes in a summary of selected published studies on seven
different histologic tumor entities (Walter B. et al., 2010; Walter
et al., 2012; Hart et al., 2015, 2016; Thomas et al., 2015; Ugocsai
et al., 2016).
Fenofibrate, retinoic acid, and vitamin D combined with
metronomic chemotherapy induced in pediatric patients
with refractory tumors of quite different histology complete
remissions (15%) (Zapletalova et al., 2012).
Long-term responses at PSA levels <0.1 ng/ml occurred
in rapidly progressive prostate cancer with PSA doubling
times <3 months using combined transcriptional modulation,
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TABLE IV | Communicative reprogramming of tumor disease.
Interferon-alpha
Neoplasia No pts Chemotherapy
(metronomic)*
Transcriptional
modulators
Small molecule Best response Publication
METASTATIC RENAL CELL CARCINOMA
Renal clear cell carinoma
Phase I trial
12 – • Interferon alpha2b
• Liposome-
encapsulated
all-trans retinoic acid
– Partial response Goldberg et al., 2002
RENAL CELL CARCINOMA RANDOMIZED
Renal clear cell carinoma 750 – • Interferon-alpha
versus
• Sunitinib Progression-free
survival superior
compared to IFNalpha
Motzer et al., 2007
Metastatic renal carcinoma
(randomized)
350 – • Interferon-alpha
versus
•
Methyl-progesterone
acetat
– Improvement in median
survival of 2.5 months
(MPA 6 months,
interferon-alpha 8.5
months)
1999
Metastatic renal cell
carcinoma (randomized)
649 – • Interferon-alpha
versus
• Interferon-alpha
plus
• Bevacizumab Interferon-alpha:
Significant
improvement in
progression-free
survival (approved)
Escudier et al., 2007
Metastatic renal cell
carcinoma
192 – • High-dose (HD)
IL-2 versus
• Il-2 plus IFN-alpha
– HD IL-2 should
remain the preferred
therapy for selected
patients with
metastatic renal cell
carcinoma (approved)
McDermott et al., 2005
MELANOMA
Melanoma, a systematic
review
– – •Interferon-alpha
(maintenance)
– No convincing
evidence of a survival
benefit
Di Trolio et al., 2015
Melanoma, resected stage
III
(randomized)
1256 – • Interferon-alpha,
adjuvant
versus observation
- Adjuvant
PEG-IFN-α-2b for
stage III melanoma:
positive impact on RFS
(marginally significant)
Eggermont et al., 2008
FOLLICULAR LYMPHOMA (RANDOMIZED)
Follicular lymphoma
(randomized)
77 Chemotherapy
± rituximab
• ±interferon-alpha
maintenance
– Improved PFS and EFS
without an impact on
OS
Herold et al., 2015
Refractory/relapsed
cutaneous T-cell lymphoma
(randomized)
370 Low-dose
MTX*
–
• Interferon-alpha
(IFN-a) versus
• IFN-a plus
Retinoids
– Overall survival
identical
Aviles et al., 2015
MULTIPLE MYELOMA
Multiple myeloma 402 – • Interferon-alpha
(maintenance after
melphalan, prednisone)
– Interferon improves
progression-free and
overall survival who
respond to
melphalan and
prednisone
Browman et al., 1995
CHRONIC MYELOCYTIC LEUKEMIA
Chronic myelocytic leukemia – – • Interferon-alpha
pegylated
• Imatinib Increases molecular
response rates
Simonsson et al., 2011
EPITHELIAL NEOPLASIA
Corneal epithelial
neoplasia
89 – • Retinoic acid and
topical interferon
alfa-2b
– Complete remission Krilis et al., 2012
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TABLE V | Communicative reprogramming of tumor disease.
Estrogene, Luteinizing hormone-releasing hormone agonist
Neoplasia No pts Chemo-
therapy
Transcriptional
modulators
Small
molecule
Best response Publication
PROSTATE CANCER
Androgen independent
prostate cancer (Phase II
study)
45 - • High dose
conjugated
estrogen
(Premarin)
- Prostate specific antigen
decreases of 50% or greater
in 25% of patients with
androgen independent
prostate cancer
Pomerantz et al.,
2007
Castration-refractory
prostate cancer
38 - • LHRH agonist,
•
Dexamethasone
• Somatostatin
analog
- Durable objective
responses
Koutsilieris et al.,
2006
Castration-resistant prostate
cancer
Review - • Somatostatin
analogs
• Estrogens
- Median survival of 10
months
Sciarra et al., 2004
ENDOMETRIAL CANCER
Endometrial cancer 16 608 - • Continuous
combined
estrogen plus
progestin
- Statistically non significant
reduction in deaths from
endometrial cancer in the
estrogen plus progestin
group
Chlebowski et al.,
2016
BREAST CANCER
Breast cancer, metastatic 32 - • High-dose
estrogen
- Antitumor effects in breast
cancer patients heavily
pretreated with endocrine
therapy
Lønning et al., 2001
BREAST CANCER (RANDOMIZED)
Adjuvant endocrine therapy
in premeno-pausal breast
cancer
927 - • Luteinizing
hormone-
releasing
hormone agonist
• Tamoxifen The combination of
goserelin and tamoxifen is
not superior to either
modality alone
Sverrisdottir et al.,
2011
BREAST CANCER
Breast cancer, prostate
cancer
- - • LHRH agonist - Long-term tumor control Sharma et al., 2008
Estrogen receptor
(ER)-alpha positive
metastatic breast cancer
Review - • LHRH analog
• Interleukin-2
- Randomized trials are
necessary
Nicolini et al., 2016
Differentiation inducing small molecules (exemplarily)
Neoplasia No pts Chemo-
therapy
Transcriptional
modulators
Small
molecule
Best response Publication
Hepatocellular
carcinoma
19 - - MTL-CEBPA,
liposomal
saRNA
Partial remission Sarker et al., 2018
Acute myelocytic
leukemia, IDH mutated
179 - - Isocitrat-
Dehydro-
genase, IDH
inhibitor
Durable remissions DiNardo et al., 2018
dexamethasone and pioglitazone in addition to metronomic
low-dose chemotherapy. Pioglitazone may activate PPARγ,
which is suggested to be a tumor suppressor in prostate
cancer (Olokpa et al., 2017). The addition of imatinib
in this schedule did not add any benefit. Interestingly,
after discontinuing the study therapy due to non-
tumor related surgery, patients remained at the status of
minimal residual disease for up to 1.5 years. Such clinical
observations are indicating anakoinosis as basis for the
development of “biologic memory” in the anakoinotically
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TABLE VI | Communicative reprogramming of tumor disease.
Retinoic acid
Neoplasia No pts Epigenetic
therapy
Transcriptional
modulators
Small molecule Best response Publication
CANCER
Cancer therapy - - • All-trans
retinoic acid (RA)
- Disruption of RA signaling
pathways: Hematological
and non-hematological
malignancies
Altucci et al.,
2007; Di Masi
et al., 2015
Advanced cancer 28 - • 9-cis retinoic
acid
- Recommended 140 mg/m2
once-daily
Miller et al., 1996
ACUTE MYELOID LEUKEMIA
Acute promyelocytic
leukemia
263 Chemotherapy
plus all-trans
retinoic acid vs.
• All-trans
retinoic acid
(ATRA)
• Arsenic
trioxide (ATO)
- Continuous complete
remission with ATRA,
ATO Approved therapy
Efficace et al.,
2014
Refractory and high-risk
acute myeloid leukemia
(AML)
– Valproic acid
(VPA)
• All-trans
retinoic acid
– In conclusion, VPA-ATRA
treatment is well tolerated
and induces phenotypic
changes of AML blasts
through chromatin
remodeling
Cimino et al.,
2006
Acute myelocytic leukemia,
refractory
5 Azacytidine
(low-dose)
• Pioglitazone,
• All-trans
retinoic acid
– Complete remission Thomas et al.,
2015; Heudobler
et al., 2018a
LYMPHOMA (RANDOMIZED)
T-cell lymphoma 377 -
Low-dose MTX*
• IFN-alpha plus
retinoid versus
Interferon-alpha
– Overall complete
response rate: 80% in
both arms
Aviles et al.,
2015
Bexarotene (retinoic X receptor agonist)
CUTANEOUS T-CELL LYMPHOMA
Cutaneous T-cell lymphoma,
phase I
23 Vorinostat • Bexarotene – Feasible if lower doses of
each drug are administered
relative to the product label
monotherapy doses
Dummer et al.,
2012
Refractory cutaneous T-cell
lymphoma
– – • Bexarotene – Complete remission;
approved
Querfeld et al.,
2006
Mycosis fungoides/Sézary
syndrome
– – • All-trans
retinoic acid
• versus
bexarotene
– Equally efficacious (historic
comparison)
Querfeld et al.,
2004
Cutaneous T-cell lymphoma,
phase I
14 – • Bexarotene Denileukin
diftitox (IL-2)
Complete remission Foss et al., 2005
Tumor-stage mycosis
fungoides
1 Vorinostat • Bexarotene
• High-dose
fenofibrate
– Complete remission Steinhoff et al.,
2008
CANCER
Cancer 52 – • Retinoid X
receptor ligand
– Partial remission Miller et al., 1997
NON-M3 ACUTE MYELOID LEUKEMIA
Acute myeloid leukemia 27 – • Bexarotene,
(phase I)
– Evidence of antileukemic
activity
Tsai et al., 2008
modulated tumor tissue (Hart et al., 2015; Vogelhuber et al.,
2015).
Besides nuclear receptor antagonists, LHRH agonists are
standard therapies in breast and prostate cancer, mostly
concomitantly integrated in therapy schedules (Graham and
Schweizer, 2016; Nourmoussavi et al., 2017; Table VIII).
The worldwide alarming incidence of advanced liver cell
carcinoma represents a great challenge for tumor therapy. An
anakoinosis inducing therapy approach, including pioglitazone,
COX-2 inhibitor and metronomic low-dose chemotherapy, has
shown a comparably favorable influence on overall survival
in advanced liver cell carcinoma, in comparison to more
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TABLE VII | Communicative reprogramming of tumor disease.
Transcriptional modulators plus pulsed chemotherapy
Neoplasia No pts Chemotherapy Transcriptional
modulators
Small
molecule
Best response Publication
LUNG CANCER
Metastatic lung cancer
(phase I)
16 Cisplatin and
epidoxorubicin plus
• Medroxypro-
gesterone acetate
• Recombinant
interleukin-2
- No significant relieve of
cancer-related cachexia
symptoms. 64% objective
response
Mantovani et al., 2000
Adenocarcinoma, lung,
heavily pretreated
23 Cyclophosphamide
plus
• Somatostatin,
• Retinoids,
• Melatonin,
• Vitamin D,
• Bromocriptine
- Improved disease-related
symptoms
Norsa and Martino,
2007
CANCER (RANDOMIZED)
Solid tumors (meta-analysis
of randomized controlled
trials)
- Concurrent
chemo-therapy or
radio-therapy
• Melatonin - Melatonin as adjuvant therapy:
Substantial im-provements in
tumor remission, 1-year survival,
alleviation of
radiochemo-therapy-related
effects
Wang et al., 2012
LYMPHOMA (RANDOMIZED)
Lymphoma: A Prospective
Evaluation in SWOG and
LYSA Studies.
777 Chemo-immune
therapy
• Low versus normal
vitamin D levels in
serum
- Low serum vitamin D levels
are associated with inferior
survival in follicular
lymphoma
Kelly et al., 2015
PROSTATE CANCER (RANDOMIZED)
Androgen-independent
prostate cancer
70 Docetaxel • Doxercalciferol - Daily doxercalciferol with weekly
docetaxel did not enhance PSA
response rate or survival
Attia et al., 2008
COLO-RECTAL CANCER (RANDOMIZED)
Advanced colorectal cancer 3254 5-Fluorouracil • Interferon-alpha - Alpha-IFN does not increase the
efficacy of 5FU or of 5FU + LV
Hill et al., 1995;
Thirion et al., 2001
CERVICAL CARCINOMA (RANDOMIZED)
Cervical carcinoma
(randomized)
209 Cisplatin plus • Retinoic acid +/-
Interferon-alpha
- No survival benefit for the
combination
Basu et al., 2016
CERVICAL SQUAMOUS CELL CARCINOMA
Metastatic cervical
squamous cell carcinoma:
Phase II trials
33 Cisplatin plus • Interferon-alpha
• Retinoids
- Objective response Braud et al., 2002
SUPPORTIV
Fertility preservation in
women with breast
cancer
- Polychemotherapy • LHRH agonist - Fertility preservation, tumor
therapy
Taylan and Oktay,
2017
sophisticated systems therapies, including sorafenib, lenvatinib
or anti-PD-1 antibodies (Walter et al., 2017). At that, an
anakoinosis inducing therapy is cost-effective, and shows a
lower toxicity rate. Therefore, a randomized comparison or a
combination with targeted therapies seems to be a logical next
step.
Demethylation Plus All-Trans Retinoic Acid
and Pioglitazone or Deacetylation Plus
Bexarotene
The combination of azacitidine plus all-trans retinoic acid and
pioglitazone may induce ex vivo granulocytic differentiation in
more of 50% of blasts from acute myelocytic leukemia (Thomas
et al., 2015). Moreover, these granulocytes regain phagocytic
activity, when exposed to E. coli (Klobuch et al., 2018). Clinically,
it is possible to induce continuous complete remission in acute
myelocytic leukemia with the triple combination, while using
only about 50% of the recommended dose of azacitidine.
Bexarotene, fenofibrate plus vorinostat may induce complete
remission in tumor-stage mycosis fungoides (Steinhoff et al.,
2008).
Classic Targeted Therapies Combined With
Anakoinosis Inducing Drugs
Among the combination of pro-anakoinotic substances
combined with classic targeted therapies are several
approved therapy schedules, interferon-α plus bevacuzimab
(Escudier et al., 2007), proteasome inhibitors combined with
dexamethasone, sandostatin plus mTor inhibitor, LHRH
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TABLE VIII | Communicative reprogramming of tumor disease.
Metronomic chemotherapy (selected randomized trials)
Neoplasia No pts Metronomic*
chemotherapy
Transcriptional
modulators
Small molecule Best response Publication
Glioblastoma (RANDOMIZED)
Glioblastoma
(randomized)
85 Temozolomide* vs.
Dose dense
temozolomide
• Sequentially
13-cis-retinoic
acid*
- No benefit of
metronomic
chemotherapy in
maintenance
Clarke et al.,
2009
OSTEOSARCOMA (RANDOMIZED)
Osteosarcoma
(adjuvant)
(randomized trial)
132
157
• Pulsed chemotherapy
plus metronomic
chemotherapy*
versus
• Pulsed chemotherapy
– - No difference in
event-free survival
Senerchia et al.,
2017
BREAST CANCER (RANDOMIZED)
Elderly breast cancer
patients (randomized)
114 ±
Cyclophosphamide*
– • Letrozol Advantage for
combination in ductal
carcinomas (first-line)
Bottini et al.,
2006
Triple-negative breast
cancer (randomized)
45 Cyclophosphamide* – ± Veliparib No benefit Kummar et al.,
2016
Her2 negative breast
cancer (randomized)
147 Capecitabine*
Cyclophosphamide*vs.
Pulsed paclitaxel
– + Bevacizumab
in each arm
Response rate 50 vs.
58%, (Not significant)
Rochlitz et al.,
2016
COLO-RECTAL CANCER (RANDOMIZED)
Colo-rectal cancer
(randomized)
558 • Capecitabine*
• Observation
– • Bevacizumab
• Observation
PFS improved for
maintenance therapy
from 8.5 to 11.7
months
Simkens et al.,
2015
Palliative therapy
pediatric cancer
(randomized vs. placebo)
108 • Etoposide* plus
Cyclophosphamide*
• Placebo
– • Celecoxib plus
thalidomide
• Placebo
PFS and OS not
significant different
Pramanik et al.,
2017
agonist plus tamoxifen (Tables I–VIII, brown). Classic targeted
therapies may be successfully combined with anakoinosis
inducing drugs, e.g., mTor-inhibitors in melanoma, or in 5th-
line in refractory Hodgkin lymphoma, or imatinib in chronic
myelocytic leukemia (CML), not achieving molecular complete
remission, or bexarotene combined with denileukin difitox in
cutaneous T-cell lymphomas (Foss et al., 2005; Hart et al., 2015;
Prost et al., 2015; Ugocsai et al., 2016).
Dual metronomic chemotherapy combined with bevacizumab
was efficacious in breast cancer: Higher baseline circulating
endothelial cells correlate with significantly improved overall
response and progression-free survival (Dellapasqua et al.,
2008).
Although, representing a specifically targeted approach,
CAR-T-cells act anakoinotic by infiltration, proliferation and
cytokine storm in the tumor tissue (Chmielewski et al.,
2014). Demethylating agents can efficiently modulate the
immunophenotype of melanoma cells (Fratta et al., 2013).
Randomized Trials
Rosiglitazone, given as monotherapy, did not delay PSA
progression in a placebo-controlled trial for prostate cancer
(Smith et al., 2004).
In a randomized trial in T-cell lymphomas, dual
transcriptional modulation with interferon-α plus retinoid
is as potent as a chemotherapy containing regimen combined
with interferon-α, but less toxic (Aviles et al., 2015). An analogous
combination, interferon-α, pioglitazone plus metronomic low-
dose chemotherapy, also shows synergistic effects in renal
cell carcinoma in a historic comparison (Reichle et al., 2007a;
Walter et al., 2012). Interferon-α has activity as maintenance
therapy in lymphomas (Herold et al., 2015). The combination of
interferon-α with lanreotide did not show any synergistic effects
in neuroendocrine tumors (Faiss et al., 2003). Monoactivity of
interferon-α is commonly weak among quite different tumor
types (Eggermont et al., 2008). Therefore, the drug did not
find its way in routine use or novel drugs are meanwhile
more active, for example in melanoma (Agha and Tarhini,
2017).
Interestingly, the anakoinosis inducing combination of
LHRH agonist, somatostatin analog plus dexamethasone is as
efficacious as pulsed chemotherapy including estramustine and
etoposide for treatment of castration-resistant prostate cancer
(Dimopoulos et al., 2004).
A randomization in metastatic melanoma highlighted
the addition of pioglitazone and COX-2 inhibitor to
metronomic chemotherapy: The triple combination resulted in
Frontiers in Pharmacology | www.frontiersin.org 14 November 2018 | Volume 9 | Article 1357
Heudobler et al. A Novel Therapeutic Pillar, Anakoinosis
FIGURE 1 | The figure indicates diversified outcomes in a summary of selected published studies on seven different histologic tumor entities (altogether 188 refractory
and metastatic patients with age, ranging from 0.9 to 83 years). By modulating therapeutically accessible communication tools (left side), homeostasis mechanisms
may be “normalized” in the tumor tissue, in the tumor-bearing organ and organism as indicated by a broad diversification of palliative tumor care or even continuous
complete remission. The right side lists the multifaceted clinically observed phenomena during anakoinosis inducing therapies. The diversified clinical outcomes
highlight clinical advantages compared to classic targeted therapies.
a significantly improved progression-free survival (Reichle et al.,
2007b).
Although gastric cancer is commonly expressing PPARγ, the
addition of pioglitazone and COX-2 inhibitor to metronomic
chemotherapy did not improve outcome in a randomized
comparison (Reichle and Hildebrandt, 2009).
Low-dose metronomic chemotherapy was not superior
compared to pulsed chemotherapy in glioblastoma patients
(Clarke et al., 2009). The addition of pioglitazone and COX-
2 inhibitor to metronomic chemotherapy led to disease
stabilization in heavily pre-treated patients with glioblastoma or
astrocytoma (Hau et al., 2007).
In T-cell lymphoma, interferon-α plus retinoid may substitute
low-dose MTX plus interferon-α (Aviles et al., 2015).
The combination arsenic trioxide and all-trans retinoic
acid outcompeted ATRA plus chemotherapy for standard risk
promyelocytic leukemia (APL) (Efficace et al., 2014).
Anakoinosis Inducing Therapy
Concomitantly or Sequentially to Pulsed
Chemotherapy
Administered as adjuvant therapy, metronomic chemotherapy
failed to show superiority, or patients only modestly benefit
despite the addition of bevacizumab in osteosarcoma or
colorectal cancer, respectively (Simkens et al., 2015; Senerchia
et al., 2017; Table VIII).
Probably, raising vitamin D levels in serum from low/sub-
normal to normal/high may contribute to a prolonged survival
following chemo-immunotherapy in lymphomas (Bittenbring
et al., 2014) whereas no advantage could be observed by the
addition of vitamin D to docetaxel in prostate cancer (Attia et al.,
2008).
The possible importance of normal or high vitamin D levels
in serum on overall survival does not seem to be restricted to
lymphoma patients treated with chemo-immune therapy, but
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there are also hints that patients following allogeneic blood stem
cell transplantation may benefit from vitamin D substitution by
a lower incidence of chronic graft-vs.-host reactions (Caballero-
Velázquez et al., 2016).
Treatment of metastatic NSCLC with pulsed chemotherapy
plus anakoinotically acting approaches including transcriptional
modulators was less successful (Mantovani et al., 2000; Norsa
and Martino, 2007). From available data one cannot conclude,
whether the combination with pulsed chemotherapy may
“destroy” anakoinotic activity profiles or the anakoinosis
inducing “cocktail” was not chosen adequately adapted to the
respective tissues’ systems pathophysiology. The addition of a
COX-2 inhibitor to pulsed chemotherapy did not significantly
improve progression-free survival in first-line therapy for non-
small-cell lung cancer (Edelman et al., 2017).
In contrast, metronomic chemotherapy plus combined
transcriptional modulation may even induce complete remission
in refractory tumors. Dual transcriptional modulation seems to
be more efficacious as indicated by the response rate, long-
term tumor control and continuous complete remissions (Reichle
et al., 2007b; Hart et al., 2015).
In lymphoma patients, differential chemotherapy schedules
may be associated with significantly different overall survival
rates, irrespective of the fact that patients received identical
prednisolone doses in each treatment arm (Bastion et al., 1997).
Interferon-α does not enhance activity of 5-fluorouracil (5-
FU) in colon cancer (Hill et al., 1995; Thirion et al., 2001).
Interferon-α plus retinoid adds no benefit to pulsed cisplatin in
cervical cancer (Basu et al., 2016).
Some Combinations of Transcriptional
Modulators Are “Supportive”
LHRH agonists are used for preserving fertility during pulsed
chemotherapy (Taylan and Oktay, 2017), like osteoprotective
regimens, such as LHRH agonist plus vitamin D (Scharla et al.,
1990).
SPECIFIC METHODOLOGICAL ASPECTS
OF ANAKOINOSIS INDUCING THERAPIES
What Is the Appropriate Dosage of
Pro-Anakoinotic Therapy?
The question for the appropriate dose of each drug in
an anakoinosis inducing schedule can be answered only
pragmatically, based on clinical results and scheduled dose
reductions, but currently, not yet pharmacokinetically (Hart
et al., 2015; Bocci and Kerbel, 2016; Ciccolini et al., 2017; Walter
et al., 2017).
Striking clinical results of anakoinosis inducing schedules are
at first glance surprising on the background that the single drugs,
particularly glitazones, have poor or nomonoactivity. This comes
true also for metronomic low-dose chemotherapy, as scheduled
dose reductions have been performed within trials up to a dose,
which would correspond to less than a quarter of the respective
3 weekly-administered cumulative dose (Hart et al., 2015; Walter
et al., 2017).
Concertedly, pro-anakoinotic drug combinations may induce
remissions, even continuous complete remissions, and may
result in diversified palliative care strategies, as shown by
multifold beneficial palliative effects in refractory neoplasia,
as summarized in Figure 1. This way, the broad spectrum of
available drugs, such as low-dose metronomic chemotherapy
and transcriptional modulators come out from the corner as
therapies validated as modestly efficacious: Once combined,
these pro-anakoinotic treatment modalities (Tables 1, 2) have
the capability for controlling refractory tumor disease. Thus,
the drug combinations obviously act concertedly as regulators
of the tumor cell systems, thereby, re-establishing apoptosis
and differentiation competence in refractory tumor disease.
Importantly, master modulators do not necessarily compromise
non-diseased, homeostatically balanced organ systems, but may
even improve organ functions (Hart et al., 2015; Walter
et al., 2017). Possible side effects, allow an early scheduled
dose reduction for avoiding further toxicity, and importantly,
without significant loss of efficacy (Walter et al., 2017).
Therapeutic efficacy despite dose reduction, particularly in case
of metronomic low-dose chemotherapy, and the fact that,
glitazones show no monoactivity in all available trials, are
indicating the pro-anakoinotic, regulatory activity profile of
the schedules (Table 1). We included metronomic low-dose
chemotherapy also in the category “master modulators”: No
evidence could be found in any reviewed clinical trial that
scheduled dose reduction would have any impact on outcome–
as far as transcriptional modulators have been additionally
administered in the study schedule (Hart et al., 2015; Walter
et al., 2017). Striking examples are the COMBAT trial for
children with refractory tumors (Combined Oral Metronomic
Biodifferentiating Antiangiogenic Treatment), and prospectively
evaluated data on scheduled dose reduction of capecitabine in
hepatocellular carcinoma; the schedule combined capecitabine
etoricoxib and pioglitazone (Zapletalova et al., 2012; Walter
et al., 2017). Reasons for a still available biomodulatory activity
at very low-doses of metronomic chemotherapy could be
synergisms between transcriptional modulators and metronomic
chemotherapy: Pioglitazone, for example, generally up-regulates
PTEN (Teresi and Waite, 2008; Berger et al., 2011), thereby,
sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil (5-
FU), which is the active metabolite of capecitabine (Cao et al.,
2007).
For monitoring anakoinosis inducing therapies it is
meanwhile realistic to establish appropriate serum analytics
(Mayer et al., 2017; Muqaku et al., 2017) to appreciate the
functional status of cell systems and their changes (Pitteri et al.,
2011). This way, we can approach the questions, which is the
lowest, still regulative active dose of a single drug, and which
are the most prominent players promoting tumor growth in the
tumor tissue and the tumor bearing organ?
Transcriptional Modulation in Cancer
Dysregulated transcription programs are an invariable
consequence of oncogenic events, and represent the backbone
of cancer (Berger et al., 2011). Dysregulation of transcriptional
networks are the reason, why cancer cells are highly dependent
Frontiers in Pharmacology | www.frontiersin.org 16 November 2018 | Volume 9 | Article 1357
Heudobler et al. A Novel Therapeutic Pillar, Anakoinosis
on regulators of gene expression (Bradner et al., 2017). Gene
regulatory network features reveal key regulatory networks
and epigenetic changes that underpin tumor disease (Jin
et al., 2018). Clusters of enhancers facilitate precise control
of gene expression across normal cellular hierarchies, and
are potential targets as central hubs in tumor disease (Bahr
et al., 2018). The use of master modulators for treatment
of metastatic refractory tumor disease, and the observed
multifaceted clinically meaningful outcomes support the
suggestion of hubs for regulation of transcriptional webs
(Reichle and Hildebrandt, 2009; Hart et al., 2015; Huang et al.,
2018).
Dysregulated transcriptional programs provide pivotal
opportunities for a series of novel therapeutic interventions in
metastatic refractory cancer (Giovannelli et al., 2012; Hart et al.,
2015; Winter et al., 2015). Despite of currently expanding data,
it is still difficult to broadly implement the current knowledge
about transcriptional addiction for patients’ benefit by targeting
oncogenic transcription factors (e.g., PMLRARA), such as in case
of acute promyelocytic leukemia (APL), resulting in substantial
clinical benefit (Cicconi et al., 2016).
The targeted blockade of tissue-specifying nuclear
transcription factors in cancer is well-established (estrogen,
progesterone, androgen receptor) (Giovannelli et al., 2012).
However, our knowledge of tissue-specifying transcription
factors remains limited, and drugs with pro-anakoinotic activity,
such as agonists of nuclear transcription factors regularly
have an activity profile far above the capacity of hermeneutic
comprehension (Reichle and Vogt, 2008).
Therapeutics, disrupting oncogenic transcription factors by
targeted protein degradation, are still clinically not approved,
but successfully studied in pre-clinical settings (Winter et al.,
2015). In pre-clinical trials, blocking of super-enhancers of
transcriptional networks is possible (Mack et al., 2018).
Master modulators in pro-anakoinotic therapy schedules
evolve tumor systems in a therapeutically meaningful way
by promoting communicative reprogramming, anakoinosis,
implicating changes of validity and denotation of cell elements,
and therefore also of cellular identity (Klobuch et al., 2018).
Vice versa, neoplasia endogenously evolves, based on anakoinotic
mechanisms. For example, hepatocellular carcinoma develops
on basis of liver cirrhosis, or aging processes in normal B-cells
precede B-cell chronic lymphatic leukemia. In case of cachexia,
the tumor even affects the whole organism via reprogramming
platelets, for example in metastatic melanoma (Mayer et al., 2017;
Muqaku et al., 2017).
Transcriptional modulation with agonistic drugs, particularly
dual transcriptional modulators, as discussed in the current
review, showed clinically meaningful efficacy in a series
of refractory metastatic neoplasia by communicatively
reprogramming transcriptional networks maintained by tumor
and adjacent stroma cells: Anakoinosis inducing approaches may
re-adapt or “normalize” homeostatic pathways (Hart et al., 2015)
by modulating functionally defined subsystems. Consecutively,
subsystems may take over novel validity and denotation for
constituting diversified rationalizations of biologic hallmarks
(Box 1; Reichle and Hildebrandt, 2009).
Therapeutically intended transcriptional networking may
have decisive regulatory impact on tumor promotion, for
instance, on the angiogenic switch or on tumor stem cell behavior
(Trosko, 2006). Targeting functionally defined subsystems
with modulators of transcription factors seems to become
of increasing interest, as subsystems within tumors may be
exclusively functionally defined in a systems context but
simultaneously linked to alternating structural systems (Pahler
et al., 2008; Reichle and Hildebrandt, 2009).
Characteristics of Master Modulators of
Tumor Tissues
Contrary to the genetic, molecular genetic and phenotypic
heterogeneity of metastatic tumor cells (Allgayer, 2018; Gerner
et al., 2018); tumor growth-promoting sub-systems supporting
hallmarks of cancer promise a high grade of similarities in
constituting hallmarks of cancer or respective tumor-specific
patterns of hallmarks. The successful administration of similar
pro-anakoinotic schedules in refractory Hodgkin lymphomas
andmalignantmelanomas, in castration-resistant prostate cancer
and multiple myeloma, or in refractory angiosarcomas and
Langerhans cell histiocytosis (Hart et al., 2015) underpins
that tumors draw on a distinct repertoire of rationalizations
supporting biologic hallmarks for constituting tumor phenotype
(Box 1; Gerner et al., 2018). Thus, similar repertoires of drug
combinations with pro-anakoinotic activity profile might be
available, which target and regulate corresponding tumor-
associated communicative subsystems mirrored for example by
inflammation-related biomarkers etc. (Reichle et al., 2007a).
How can we integrate the finding that different histologic
tumor types may share tumor response to distinct combinations
of master modulators (Hart et al., 2015).
Recurring oncogenic events, such as alterations of NF-κB,
TGFβ, Ras, p53, Myc, E2F/Rb/CDKN2, are associated with
multifold tumor phenotypes (Ahmadiyeh et al., 2010): This
observation explains that the tissue of origin predominantly
characterizes tumor phenotypes as indicated by histology. The
tumor phenotype depicts the recessive and thus, therapeutically
accessible communicative interactions occurring during tumor
evolution according to the restrictions given by the tissue-specific
“metabolism” of evolution.
The tissue-specific “metabolism” of evolution makes different
cancer types sharing similar tissue disruptions, alterations
in homeostatic pathways and dysregulation of transcription
factors, as tumor evolution deeply interweaves ubiquitously
available wound healing mechanisms, inflammation, immunity,
angiogenesis and metabolic processes (Virchow, 1859; Dvorak,
2015).
So-called super-enhancers spatially and temporally coordinate
transcriptional webs for maintaining cell identity. Eqipollent,
the neighboring environment communicatively mediates
cellular identities (Reichle, 2013). Accordingly, synchronized
“super enhancers” are responsible for higher order spatial re-
organization of chromatin clusters that finally define cell identity
(Hnisz et al., 2013). Oncogenic events must draw on such
super-enhancers for establishing tumor-associated conditions
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described by the observation that tumors behave like never
healing wounds (Virchow, 1859; Dvorak, 2015). Transcriptional
super-enhancers may also explain convergence of developmental
and oncogenic signaling pathways and their unique therapeutic
accessibility (Hnisz et al., 2015).
Clinically observable changes in cell identities as indicated
for example by differentiation of blasts from acute myelocytic
leukemias and regain of granulocytic functions, suggest
therapeutically important modifications of super-enhancers by
pro-anakoinotic, transcriptionally active drugs (Hnisz et al.,
2013; Hart et al., 2015; Sim et al., 2017; Klobuch et al., 2018).
Figure 1 summarizes that cellular identity compromising tumor
biologic changes are as expected, highly diversified, with strong
impact on outcome. Interestingly, pre-clinical activities of
inhibitors of super-enhancers among different tumor types are as
multifaceted as clinical results presented in Figure 1 (Sengupta
and George, 2017).
“Biologic memory” or long-term response in castration-
resistant prostate cancer exemplifies the possibility for “active”
chronifying tumor disease. Induction of molecular complete
remission via differentiation induction could be observed in
acute myelocytic leukemia or delayed objective response in
renal clear cell carcinoma with consecutive continuous complete
remission. Interestingly, combinatorial use of transcriptional
modulators seems to be even more efficacious concerning
outcome of refractory metastatic tumor disease (Koutsilieris
et al., 2006; Hart et al., 2015).
An anakoinosis inducing schedule in hepatocellular
carcinomas clinically demonstrated that the discrimination
of local or metastatic disease has no significant impact on
overall survival (Walter et al., 2017). By using the appropriate
pro-anakoinotic therapy approach the suggested genetic
heterogeneity at metastatic sites plays a minor role for outcome.
These results highlight the novel pathophysiologic concept as
basis for pro-anakoinotic therapies (Reichle and Hildebrandt,
2009).
Glitazones are the most frequently used transcriptionally
active master modulators for anakoinosis induction besides
glucocorticoids (Heudobler et al., 2018b). For example,
pioglitazone, a peroxisome-proliferator-activated receptor
(PPAR) γ/α agonist, seems to be an important many-sided
applicable master modulator for communicative processes
in neoplasia. Despite the missing monoactivity of glitazones
in cancer (Table 1), pioglitazone is highly efficacious in
combination with metronomic low-dose chemotherapy, or
epigenetically active drugs (azacitidine), plus/minus further
transcriptional regulators (interferon-α, dexamethasone or
all-trans-retinoic acid (ATRA) (Tables I–VIII): After 3 years,
the median overall survival has not been reached in a study
on castration-resistant prostate cancer (Vogelhuber et al.,
2015). In refractory Langerhans cell histiocytosis (Reichle
et al., 2005; Heudobler et al., 2016), and (hem-) angiosarcomas
continuous complete remissions have been observed (Vogt et al.,
2003). Also in refractory acute myelocytic leukemia (Thomas
et al., 2015) molecular complete remissions occurred, indeed
by differentiation of blasts in phagocytic active neutrophils
(Figure 1; Klobuch et al., 2018), but also by rescuing healthy
hematopoietic maturation while repressing leukemic growth
(Boyd et al., 2017). The addition of pioglitazone to imatinib in
chronic myelocytic leukemias, not responding with molecular
complete remission (MCR) may induce in a high percentage
of patients MCR (Rousselot et al., 2017). In hepatocellular
carcinoma, clinical data give hints that pioglitazone combined
with metronomic low-dose chemotherapy and COX-2 inhibitor
may communicatively reprogram in a clinically meaningful way
the cirrhotic liver, tumor microenvironment and carcinoma cells
(Walter et al., 2017).
Master modulators might interfere with master transcription
factors and mediators establishing super-enhancers at key cell
identity genes (Whyte et al., 2013). For example, PPARγ
binds to the promoter of Dlc1 gene, a super-enhancer to
regulate its expression during both white and brown adipocyte
differentiation (Sim et al., 2017).
Performing studies on PPARγ in tumor cell cultures only,
without co-culturing heterologous stroma derived cells leads
to the conclusion that PPARγ may also function as a tumor
promoter (Yun et al., 2018). Co-culturing tumor cells, however,
with tumor-associated fibroblasts and dual stimulation with
nuclear transcription factor agonists consistently results in tumor
response within quite different histologic tumor types (Papi et al.,
2009, 2010, 2012, 2013). In vivo, PPARγ agonists promote cell
cycle arrest, cell differentiation (Klobuch et al., 2018; Ryu et al.,
2018), and apoptosis and reduce inflammation (Hart et al., 2015),
angiogenesis, oxidative stress, cell proliferation, invasion (Reichle
and Vogt, 2008), and cell migration (Vallée and Lecarpentier,
2018).
Many pre-clinical data indicate that pioglitazone up-regulates
non-mutated tumor suppressor genes and consecutively
modulates homeostatic pathways in tumor tissues (Mulholland
et al., 2005; Teresi and Waite, 2008; Berger et al., 2011; Rosner
et al., 2017; Walter et al., 2017; Vallée et al., 2018). Mutations
in the PPARγ gene are rare in neoplasia. Follicular thyroid
cancer harbors a fusion gene (Eberhardt et al., 2010): A trial
with pioglitazone is ongoing (ClinicalTrials.gov Identifier:
NCT01655719).
Follow-up studies of the ProActive trial do not support any
more the possibility that pioglitazone may favor the development
of urothelial carcinoma in patients with diabetes mellitus type II
(Erdmann et al., 2016).
Pro-Anakoinotic Therapy Schedules:
Indications and Diagnostics
Transcriptional modulators are master modulators of tissue
communication and are important pro-anakoinotic drugs,
with obvious combinatorial activity among themselves,
combined activity with metronomic low-dose chemotherapy,
demethylating agents, pulsed chemotherapy or classic targeted
therapy. It remains striking that the combinatorial use of
the defined anakoinotic active drugs (Table 1) may induce
(continuous) complete remission in refractory tumor disease.
All these observations prompt the assumption that
irrespectively of the therapeutic technique for achieving
apoptosis competence, either classically targeted, or with a
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cytotoxic approach, or by communicatively reprogramming a
tumor disease, anakoinotic mechanisms are essentially necessary
for finally initiating mechanisms, paving the way for continuous
complete remission.
Assuming differential sequential biologic steps, necessary
for achieving long-term tumor control in case of metastatic
tumor disease (Beyar-Katz et al., 2016; Was et al., 2018),
induction of anakoinosis opens the window for an
active guidance and specified therapeutic support for
re-establishing apoptosis or differentiation competence.
Anakoinosis focuses on therapeutically guiding dynamic
communication processes linked to tumor evolution or
tumor response (Beyar-Katz et al., 2016; Was et al., 2018).
More static evaluations of tumor characteristics, such
as histology, immunohistology, molecular genetics and
genetics serve as starting point for classic targeted therapies.
Classic pathology-associated tumor evaluation includes
parameters, which are mostly heterogeneous at metastatic sites
(Figure 1).
In contrast, similarities of cellular immune response at
primary site and metastatic sites of renal cell carcinoma or
colorectal cancer (Remark et al., 2013) underline that tumor
heterogeneity may be principally therapeutically overcome
by pro-anakoinotic therapy approaches. Thus, evaluation of
the respective “evolution-adjusted” tumor pathophysiology,
such as homeostatic mechanisms, down-regulated tumor
suppressor genes, transcriptional dysregulation etc., may in
future diagnostically guide the selection of pro-anakoinotic
schedules (Figure 1; Reichle, 2013).
Besides their function as rescue therapies for refractory
neoplasia, anakoinosis inducing therapy schedules might
supplement or substitute known consolidation therapies, such
as continuous long-term maintenance therapy (Rousselot et al.,
2017), adjuvant chemotherapies, or high-dose chemotherapy
combined with autologous stem cell transplantation:
Preliminarily results from clinical trials already indicate
that anakoinosis inducing schedules may decisively influence
long-term outcome (Tables I–VIII). For example, in chronic
myelocytic leukemia without molecular remission (Rousselot
et al., 2017) the addition of pioglitazone to imatinib may
induce continuous complete remission: Even a discontinuation
of imatinib and pioglitazone is possible. In patients with
lymphoma serum vitamin D levels (Kelly et al., 2015; Prost
et al., 2015) are predictive for overall survival. Lenalidomide is
well established as maintenance therapy in multiple myeloma,
all-trans retinoic acid in promyelocytic leukemia (Cicconi et al.,
2016; McCarthy et al., 2017). Unfortunately, many chosen
anakoinotic acting maintenance therapies showed modest
improvement of progression-free survival, failed to demonstrate
any important clinical effects or not used any more due to
the availability of novel targeted therapies (Browman et al.,
1995; Di Trolio et al., 2015; Simkens et al., 2015; Rochlitz et al.,
2016).
Pro-anakoinotic therapy schedules might be the ideal
adjuvants for classic targeted therapies efficaciously controlling,
even eradicating disseminated neoplasia (Hart et al., 2015; Prost
et al., 2015; Neelapu et al., 2017).
Generally, anakoinosis inducing therapies are characterized
by a favorable toxicity profile (Dimopoulos et al., 2004;
Zapletalova et al., 2012; Hart et al., 2015; Cicconi et al., 2016;
Rousselot et al., 2017; Figure 1).
Acknowledgment of a Novel Therapy
Concept
The review shows that even refractory metastatic tumor
disease may respond to induction of anakoinosis: Moreover,
independent of the histologic tumor type, anakoinosis inducing
therapies are available for the successful treatment of refractory
metastatic tumor stage (Figure 1).
Four communication-derived targets are accessible for
anakoinosis-inducing therapy approaches: Figure 1 summarizes
clinically observed events induced by anakoinosis in metastatic
(refractory) neoplasia (Hart et al., 2015; Walter et al., 2017).
Clinical results from anakoinotic therapy approaches
may topographically map four communication levels: Pro-
anakoinotic combination therapies simultaneously modulate
the single cell phenotype (Klobuch et al., 2018), but also tumor-
stroma-cell, tumor-organ (Hart et al., 2016) and tumor-organism
interactions (Muqaku et al., 2017), as particularly indicated
in metastatic hepatocellular carcinoma or (uveal) melanoma
(Hart et al., 2016; Walter et al., 2017). The clinical results depict
also four communication tools, available for targeting: The
holistic communicative system, i.e., specific tumor-stroma-
organ-organism interactions, modularity, rationalizations, i.e.,
the physical constitution of biologic hallmarks‘, and the specific
metabolism of evolution, given by a distinct cellular context at
an organ site (Box 1).
Known prognostic parameters, such as therapy refractoriness
in neoplasia, the specific mutations in Philadelphia chromosome
in chronic myelocytic leukemia (Rousselot et al., 2017),
FLT3 positivity in acute promyelocytic leukemia treated
with all-trans retinoic acid plus arsenic trioxide (Cicconi
et al., 2016), may ultimately lose their exclusive unfavorable
prognostic significance by induction of anoikis, programmed
cell death (Hart et al., 2015). Particularly, metronomic low-dose
chemotherapy plus pioglitazone and COX-2 inhibitor separated
PPARγ expression as late-stage prognostic parameter (Meyer
et al., 2009).
The evidences are so strong as to indicate that anakoinosis
represents a substantive therapy principle besides novel
targeted therapies. Routine pathophysiological studies including
homeostatic pathways, down-regulated tumor suppressor genes
etc. are now in the center of diagnostic interest for guiding
pro-anakoinotic therapy approaches. Here we still find a big
diagnostic gap (Figure 1).
PERSPECTIVES
Do tumor systems’ complexity and the myriad of reductionist
therapeutic approaches targeting separately tumor or stroma
cells precede the simplicity of anakoinosis inducing treatment
strategies (Reichle and Hildebrandt, 2009)?
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Anakoinosis may induce a broad spectrum of palliative effects,
moreover, continuous complete remission in refractory neoplasia
(Hart et al., 2015). Indeed, anakoinosis inducing therapies may
circumvent the problem of “undruggable targets” and cope with
the general therapeutic problem of (molecular-) genetic tumor
heterogeneity (Walter et al., 2017). In addition, pro-anakoinotic
schedules may directly target tumor stem cells (Katoh and Katoh,
2007; Prost et al., 2015; Zhang et al., 2016; André et al., 2017).
The basic concept looms that fixed combinations of pro-
anakoinotically acting drugs are available for treatment of quite
different tumor histologies. Nevertheless, the respective therapy
“cocktails” may be adopted according to specific, convergent
organized systems rationalizations of cancer hallmarks, probably
shared by different tumor histologies (Box 1; Hart et al., 2015).
Pro-anakoinotic therapies may be specified according to the
tumors’ ontology (e.g., liver cirrhosis, myelodysplasia etc.), but
also directed to the individual response patterns of the organism
in response to the tumor disease, for example in case of
cachexia (Hart et al., 2015; Muqaku et al., 2017). These multi-
level communication tools are becoming accessible now by
anakoinosis inducing therapy approaches, and spotlight again
the impact of multi-dimensional communication levels on tumor
promotion. We are just in the beginnings for appropriate
diagnostic and therapeutic steps in this direction.
Anakoinosis inducing therapies successfully integrate many
supplementary classic targeted approaches, as shown by initial
results with mTor inhibitors, imatinib and bevacizumab,
respectively (Table 1).
Anakoinotic processesmay principally cope with fundamental
obstacles of classic targeted therapies, with tumor heterogeneity
and poor risk parameters, with context-dependent validity and
denotation of tumor-promoting aberrations and targets, with
drug resistance or undruggable targets by targeting dynamic
evolutionary processes, for example multifaceted biologic steps
necessary for establishing “active” long-term tumor control
or continuous complete remission due to drug and tumor
specific host responses (Box 1; Hart et al., 2015). Pro-anakoinotic
therapies may inhibit further metastatic progression in case of
metastatic disease (Figure 1; Reichle and Vogt, 2008).
A series of multicenter randomized phase II trials with
anakoinosis inducing therapies, initiated by the University
Hospital Regensburg, currently enrolling, include refractory
acute myelocytic leukemia, castration-refractory prostate cancer,
metastatic melanoma and non-small cell lung cancer. Large
European trials on promyelocytic leukemia or chronicmyelocytic
leukemia are on the way.
Anakoinosis provides a novel therapy strategy for controlling
even therapy-resistant metastatic tumor disease. The novel
therapy principle draws on “old” drugs, and promotes drug
repurposing in a rational way, oriented at recessive tumor
associated events (Hart et al., 2015; Boyd et al., 2017;Walter et al.,
2017).
Tissue engineering procedures may also implement
anakoinosis for integrating multiple cell systems.
By introducing pro-anakoinotic schedules, innovation must
not be adapted to local budget constraints to meet an area’s
need, e.g., in low-budget countries (Bouche, 2017), but may be
universally applicable as novel therapeutic principle.
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